Journal article

State-of-the-art in the pneumococcal field: Proceedings of the 11(th) International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11)

Brenda Anna Kwambana-Adams, E Kim Mulholland, Catherine Satzke, Heidi Smith-Vaughan, Angela Brueggemann, Cynthia Whitney, Lea-Ann Kirkham, Raquel Sa-Leao, Jorge Vidal, Hamish Graham, David Murdoch, Glaucia Paranhos-Baccala, David Goldblatt, William S Pomat, Emma Best, Peter McIntyre, Jodie McVernon, Daniel Weinberger, Eileen Dunne, J Anthony Scott Show all



The International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) is the premier global scientific symposium dedicated to the exchange, advancement and dissemination of the latest research on the pneumococcus, one of the world's deadliest bacterial pathogens. Since the first ISPPD was held in 1998, substantial progress has been made to control pneumococcal disease, for instance, more than half of surviving infants (78.6 million) from 143 countries now have access to the life-saving pneumococcal conjugate vaccine (PCV). The 11th ISPPD (ISPPD-11) was held in Melbourne, Australia in April 2018 and the proceedings of the symposium are captured in this report. Twenty years on from the ..

View full abstract


Funding Acknowledgements

We are grateful to the ISPPD-11 major sponsors: The Bill & Melinda Gates Foundation, Pneumonia, GlaxoSmithKline (GSK), Pfizer and MSD. We also thank the general sponsors: PATH, Serum Institute of India as well as sponsors IVAC, LimmaTech Biologicals, City of Melbourne, Melbourne and Convention Bureau.